Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

AB045. Novel gene therapy for erectile dysfunction

Clinical Trial on Systemic / IV, published in Transl Androl Urol (2015) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Transl Androl Urol (2015)
Reported sample size
—
Source database
Europe PMC
PMCID
PMC4708833

Abstract (original English)

Objective Erectile dysfunction (ED) is a major health problem that affects millions of men all around the world. Since a significant number of ED patients have a poor response to the first line oral phosphodiesterase 5 inhibitors, underlying treatment like gene therapy is needed to evolve as a promising solution. Methods Basic and clinical researches regarding the application of gene therapy for ED over this few decades were reviewed. Then we summarize the state-of-the-art development of therapeutic targets, transfection methods, model systems and their efficacy in this field. Results All gene therapy studies are still in preclinical phase except one clinical trial using the target of Ca2+-activated, large-conductance K+ channel. In basic researches, animal models of ED induced by aging, diabetes, cavernous nerve injury, hypertension, hypercholesterolemia have been utilized to evaluate the capacities and mechanisms of therapeutic targets to improve ED. In addition to the classic transfection methods like naked plasmid DNA, liposome and virus, new gene therapy vectors such as stem cells come into stage and present specific advantages. Besides, novel systems are invented to optimize the process of transfection. These researches demonstrate that current selected targets are widely involved in multiple erection related signaling pathways and all of them present exciting results. Al

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research